Medite Cancer Diagnostics MDIT · USD

Its shares trade under the ticker MDIT. It has been listed since 27 October 1993. In the fiscal year to 31 December 2017, it reported revenue of $6.8m and a net loss of $6.8m. At that date it held total assets of $16.0m and shareholders' equity of $5.8m.

MEDITE Cancer Diagnostics, Inc. is a medical technology company which engages in cancer diagnostics instruments and consumables for histology and cytology laboratories. The company is headquartered in Chicago, Illinois. The firm develops, manufactures and sells a range of laboratory devices and consumable supplies for its target market in the histology and cytology cancer diagnostics segment. The firm offers a range of histology laboratory devices for processing tissue, from receiving the tissue in the laboratory to the final diagnosis. The firm offers USE33, an ultrasonic decalcification instrument that runs the process under controlled temperatures. The firm also offers TPC15 Duo or Trio, TES99, TES Valida, M530, A550, M380, TST44 and COT20 linear staining systems. In addition, the Company also offers RCM9000, ACS720 and TWISTER glass and robotic coverslippers.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. William LewisIndependent Chairman of the Board$55,000
• Mrs. Michaela OttChief Operating Officer, since 2014$149,784
• Mr. Jeff RencherChief Marketing and Business Development Officer
• Mr. Gregory FortunoffDirector
• Dr. John AbelesIndependent Director$35,000
• Mr. Joel KanterIndependent Director
• Mr. Alexander MilleyIndependent Director$20,000

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.